Related references
Note: Only part of the references are listed.How the Cluster-randomized Trial Works
James C. Hurley
CLINICAL INFECTIOUS DISEASES (2020)
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre
Martin Lukas et al.
JOURNAL OF CROHNS & COLITIS (2020)
Shift From Adalimumab Originator to Biosimilars in Denmark
Thomas Bo Jensen et al.
JAMA INTERNAL MEDICINE (2020)
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study
Davide Giuseppe Ribaldone et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2020)
Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial
Kathrine L. Gron et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)
Stanley B. Cohen et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The limitations of observation studies for decision making regarding drugs efficacy and safety
Francois Gueyffier et al.
THERAPIE (2019)
Era of biosimilars in rheumatology: reshaping the healthcare environment
Josef S. Smolen et al.
RMD OPEN (2019)
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
Mark C. Genovese et al.
ARTHRITIS RESEARCH & THERAPY (2019)
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
Stanley Cohen et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4 Six-Month Results From a Controlled Cohort Study
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries
B. Glintborg et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2018)
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
Hendrik Schulze-Koops et al.
RHEUMATOLOGY (2017)
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Till Uhlig et al.
RHEUMATOLOGY (2017)
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry
Else Helene Ibfelt et al.
CLINICAL EPIDEMIOLOGY (2017)
Biosimilars: Implications for Clinical Practice
Robert M. Rifkin et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Long-Term Clinical Outcomes After Switching from RemicadeA® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Lisa J. T. Smits et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Filipe C. Araujo et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
Biosimilars: New or Deja Vu?
Jonathan Kay
ARTHRITIS & RHEUMATOLOGY (2016)
The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO
Else Helene Ibfelt et al.
CLINICAL EPIDEMIOLOGY (2016)
Biosimilar safety factors in clinical practice
Walter Reinisch et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
The Danish National Patient Registry: a review of content, data quality, and research potential
Morten Schmidt et al.
CLINICAL EPIDEMIOLOGY (2015)
Inequities in access to biologic and synthetic DMARDs across 46 European countries
Polina Putrik et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The Danish Civil Registration System as a tool in epidemiology
Morten Schmidt et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
Using natural experiments to evaluate population health interventions: new Medical Research Council guidance
Peter Craig et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2012)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
Observational Studies Analyzed Like Randomized Experiments An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease
Miguel A. Hernan et al.
EPIDEMIOLOGY (2008)
Randomized, controlled trials, observational studies, and the hierarchy of research designs.
J Concato et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
